Publicaciones en colaboración con investigadores/as de Hospital Universitario San Cecilio (97)

2024

  1. Feasibility and Short-Term Outcomes in Liver-First Approach: A Spanish Snapshot Study (the RENACI Project)

    Cancers, Vol. 16, Núm. 9

  2. Impact of Remote Monitoring on Standardized Outcomes in Nephrology-Peritoneal Dialysis

    Kidney International Reports, Vol. 9, Núm. 2, pp. 266-276

  3. Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 712-721

  4. Textbook outcomes in the liver-first approach for colorectal liver metastases: prospective multicentre analysis

    BJS Open, Vol. 8, Núm. 1

  5. Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study

    International Journal of Dermatology

  6. [Translated article] Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

2023

  1. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain

    International Journal of Dermatology, Vol. 62, Núm. 5, pp. 700-706

  2. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus

    Acta Dermato-Venereologica, Vol. 103

  3. Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

  4. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

    Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997

  5. Upadacitinib for moderate to severe atopic dermatitis

    Immunotherapy, Vol. 15, Núm. 11, pp. 799-808

  6. Updated Review on Treatment of Atopic Dermatitis

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 3, pp. 158-167

2022

  1. Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)

    Life

  2. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

    JHEP Reports, Vol. 4, Núm. 5

  3. Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: A cohort study

    F1000Research, Vol. 11

  4. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis

    Dermatologic Therapy, Vol. 35, Núm. 10

  5. Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab

    Dermatologic Therapy, Vol. 35, Núm. 11

  6. HEPATITIS C VIRUS SCREENING AND LINKAGE TO CARE IN MENTAL HEALTH UNITS: AN OPPORTUNITY FOR HCV ELIMINATION

    Actas espanolas de psiquiatria, Vol. 50, Núm. 2, pp. 120-121

  7. High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use

    Journal of Infection, Vol. 85, Núm. 3, pp. 322-326

  8. Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review

    Life, Vol. 12, Núm. 8